The state of South Carolina currently has 14 active clinical trials seeking participants for Pulmonary Fibrosis research studies. These trials are conducted in various cities, including Charleston, Greenville, Spartanburg and Columbia.
Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF
Recruiting
This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. GRI-0621 dose of 4.5mg will be compared with placebo following once daily oral administration for 12 weeks. Concurrently, a Sub-Study will be conducted, examining the number and activity of NKT cells in BAL, for up to 12 eligible subjects (across various centers). An interim analysis will... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
07/23/2024
Locations: MUSC Pulmonary Research, Charleston, South Carolina
Conditions: Idiopathic Pulmonary Fibrosis
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Recruiting
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
04/16/2024
Locations: The U.S. Department of Veterans Affairs, Charleston, South Carolina +1 locations
Conditions: Idiopathic Pulmonary Fibrosis